FDBusiness.com

AB-Biotics seeks partners at Vitafoods Europe to market its cholesterol-lowering and IBS probiotics

 Breaking News
  • Ferrero to Acquire US Confectionery Company Ferrero Group is acquiring Ferrara Candy Company, the third largest non-chocolate confectionery company in the US, from L Catterton, the biggest and most globally consumer-focused private equity firm in the world. The terms of the transaction were not disclosed. Ferrara is best known as the maker of iconic brands such as Trolli, a leader in [...]...
  • Shift to Sustainable Food System in Europe is Possible – But Faces Challenges Making Europe’s production, consumption and trade in food environmentally sustainable is possible, but it will require a major shift in public attitudes, policies and knowledge and seizing current opportunities for change, according to a newly published European Environment Agency (EEA) report. The EEA report ‘Food in a green light,’ analyses the challenges Europe faces in shifting [...]...
  • Pet Food Producer Achieves 30% OEE Improvement and Brand Security With OAL Connected Wagg Foods, a leading producer of high-quality pet food, has increased its OEE efficiency by 30%, secured its packaging lines from errors and ensured full compliance with retailers’ code of practice with OAL Connected, a modular suite of packaging line software. Known for its laser-focus on quality, nutrition and product development, Wagg Foods prides itself on [...]...
  • Thirsty Business – How Water Reuse Can Benefit the Food and Beverage Industry By Martin Kunz, EMEA Segment Leader, Industry for Xylem’s Applied Water Systems business Only 2.5 percent of the world’s water is fresh water, and of that, only one percent is accessible as much is trapped in glaciers and snowfields. By one estimate, global fresh water demand will exceed supply by 40 percent in 2030 if current [...]...
  • Hilton Food Group to Move into UK Fish Processing Hilton Food Group, the UK-based specialist international meat packing business, has agreed to acquire Icelandic Group UK (Seachill), a leading chilled UK fish processor, for cash consideration of £80.8 million. The acquisition will provide Hilton with entry into the processing and supply of fish in the UK. Robert Watson OBE, chief executive of Hilton Food Group. Founded [...]...

AB-Biotics seeks partners at Vitafoods Europe to market its cholesterol-lowering and IBS probiotics

May 21
11:06 2012
  •  The Spanish biotech company looks for pharma or food companies interested in selling these IP-protected and clinically tested nutraceuticals, AB-LIFE and I3.1, in Europe and around the world

Barcelona (Spain).- The Spanish biotech company AB-Biotics presents these days at Vitafoods Europe, in Geneva, its  new probiotics AB-LIFE and I3.1, focused on the prevention and treatment of cholesterol and irritable bowel syndrome, respectively. The company wants to contact pharma or food companies interested in licensing these functional ingredients in the European. market and / or worldwide.

This important meeting is held in Geneva from 22th to 24th May. AB-Biotics wants to take advantage of this international showcase to look for licensors for two revolutionary probiotics. “The applications of AB-LIFE and I3.1 for the industry are very diverse, so in recent months several companies from different countries have already expressed interest in a possible license agreement”, said Sergi Audivert and Miguel Angel Bonachera, CEOs of AB-Biotics.

 

AB-LIFE: the first probiotic therapy in preventing cardiovascular disease

AB-BIOTICS is looking for pharmaceutical companies interested in licensing AB-LIFE in new markets. AB-LIFE is a nutritional ingredient which reduces cholesterol levels by 14%, according to clinical studies performed by Hospital Puerta del Hierro inMadrid. In addition to its greater efficacy, this new ingredient has another important difference in comparison with other solutions in the market: it not only reduces the levels of cholesterol ingested in the diet, but also blood cholesterol levels, leading to increased effectiveness in a larger number of people. 

With AB-LIFE, the Spanish company AB-BIOTICS has opened the door to probiotic therapy in preventing cardiovascular disease. As well as its possible use in the form of capsules, AB-LIFE can be added to foods with no thermal treatment, such as dairy products, or to drinks or juices using encapsulation techniques. AB-Biotics has already signed agreement agreements with different companies to distribute AB-LIFE in Southeast Europe, particularly in the markets of Slovenia, Croatia, Bosnia-Herzegovina, Serbia, Montenegro, Macedonia and Albania; and also Spain and Brazil.

 

I3.1: a better quality of life for IBS patients

Irritable Bowel Syndrome (IBS) is considered to be the most common gastrointestinal disorder. Its prevalence in western world is estimated to be 10-15% of the adult population. Current treatments for IBS have limited efficacy and severe side effects have been reported in recently approved drugs. AB-BIOTICS has developed I3.1, the first probiotic formula which produces a global improvement of quality of life in IBS patients.

I3.1 consists of a combination of three lactic acid bacteria, more precisely two Lactobacilli and one Pediococcus. Strains in I3.1 formula are able to produce high amounts of short chain fatty acids, especially, butyric acid. SCFAs are readily absorbed by intestinal mucosa and are known to stimulate serotonin release, which modulates both gut motility and sensation. Therefore, in situ production of SCFAs by strains of the I3.1 formula is useful to modulate gut motility and reduce visceral pain. Moreover, I.31 has displayed significant anti-inflammatory activity in two different animal models of gut inflammation, reducing both external symptoms of IBS and molecular markers. Also, 3.1 displays a significant inhibitory activity against many pathogenic bacterial strains, while allowing the growth of common commensal bacteria of the human gastrointestinal flora. Clinical trial has confirmed that I3.1 makes a positive improvement in health-related quality of life of IBS patients, reducing gastrointestinal discomfort and pain. “AB-BIOTICS is looking for pharmaceutical companies interested in licensing I3.1 in different markets –said Sergi Audivert and Miquel Àngel Bonachera, CEOs of AB-BIOTICS-. The product can be dosed both in capsules, tablets and sachets, with a product stability of at least 2 years”.

 

About AB-BIOTICS

AB-BIOTICS is a Spanish biotechnology company focused on research, development, protection and distribution of its own exclusive biotechnological solutions.  The company’s mission is to improve the health and wellbeing of people. The company has an innovative philosophy and its own know-how that allows it to develop avant-garde products with high added value for the market.

 Since 2010, ABBIOTICS is listed in the Alternative Investment Market (MAB, in Spanish). The company has just started its international expansion plan, in order to reinforce their commercial activity and be present in high-potential countries like theUnited States, theUnited Kingdom,Germany,France,Turkey,Mexico andBrazil.

 

More information: http://www.ab-biotics.com/
Nuria Peláez – Communications officer
pelaez@ab-biotics.com
0034 654 352 541

About Author

colin

colin

Related Articles



Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • October 19, 2017PMA Fresh Summit 2017
  • October 21, 2017Food & Nutrition Conference & Expo 2017
  • October 22, 2017Serbotel
  • October 22, 2017Natexpo
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber





Subscribe Here



Advertisements